

<b>Reference:</b>	FOI.6484.21
<b>Subject:</b>	Oesophageal and gastric cancer
<b>Date of Request:</b>	16 July 2021

**Requested:**

1. Does your trust treat the following conditions?
  - Advanced oesophageal cancer
  - Advanced gastric cancer
  - In case you do not treat either of the above conditions, which other trust do you refer these patients to?
  
2. Please provide the total number of patients treated in the last 6 months for
  - Oesophageal cancer (any type)
  - Oesophageal adenocarcinoma
  - Oesophageal squamous cell carcinoma
  - Unresectable oesophageal squamous cell carcinoma
  - Gastric cancer (any type)
  - HER2 negative or HER2 untested gastric cancer
  
3. For oesophageal squamous cell carcinoma only, how many patients were treated in the past 6 months with:
  - Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
  - Any other systemic anti-cancer therapy
  - Palliative care only
  
4. For gastric cancer only, how many patients were treated in the past 6 months with:
  - CapeOx (Capecitabine with Oxaliplatin)
  - FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
  - Any other systemic anti-cancer therapy
  - Palliative care only
  
5. Does your trust participate in any ongoing clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part.
  
6. Does your trust participate in any ongoing clinical trials for the treatment of gastric cancer? If so, can you please provide the name of each trial and the number of patients taking part.

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, as well as locating, retrieving and extracting the information.

The ChemoCare team, who hold a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients' medical records to establish the type of cancer diagnosed and therapies used to treat the patients. It is estimated that conducting this search would take longer than the 18 hour 'appropriate limit' as stated within the Freedom of Information Act 2000 (FoIA).

The UHB is therefore applying an exemption under Section 12 of the FoIA, which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, we are required, as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. We therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB, who may be able to help you with your enquiry. The contact details are as follows:-

[FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk) or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.